Tatiana Schlossberg, 35, granddaughter of JFK, revealed her struggles with acute myeloid leukemia diagnosed hours after giving birth in May 2024. Her white blood cell count spiked to 131,000, far above the normal 4,000–11,000, illustrating the urgency of her situation.
She described the shock: “I did not — could not — believe that they were talking about me… I wasn’t sick…. I didn’t feel sick. I was actually one of the healthiest people I know” on 23 November 2025. Her story foreshadows the deeper family and policy conflicts to come.
The Controversial Cousin
Robert F. Kennedy Jr., serving as U.S. Health and Human Services Secretary, announced the termination of $500 million in federal mRNA vaccine funding on 5 August 2025. His actions immediately placed him at odds with public health priorities and the Kennedy family legacy.
RFK Jr. justified the cuts: “We reviewed the science, listened to the experts, and acted. BARDA is terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu” on 6 August 2025. The implications ripple far beyond Washington.
A Mother’s Warning
Caroline Kennedy, Tatiana’s mother, openly opposed RFK Jr.’s confirmation on 28 January 2025. She called him “a predator” and said: “I’ve known Bobby my whole life. It’s no surprise that he keeps birds of prey as pets because Bobby himself is a predator.”
She further warned, “Bobby preys on the desperation of parents of sick children, vaccinating his own kids while building a following hypocritically discouraging other parents from vaccinating theirs” on 28 January. Her concern hints at the widespread healthcare consequences Tatiana would soon confront.
Widespread Research Fallout
The NIH and BARDA experienced sweeping disruptions. Since February 2025, 4,400+ grants ended, totaling $800 million in cancer and infectious disease programs cut. 383 clinical trials were interrupted, affecting 74,311 patients, with 35% still actively recruiting.
Major mRNA projects terminated included Emory University, Tiba Biotech, and Moderna’s H5N1 contract. Smaller firms such as Luminary Labs, ModeX, and Seqirus faced de-scoping. However, the broader impact on patients’ lives was just beginning to surface.
Personal Stakes Revealed
Tatiana expressed the personal cost of these policy decisions: “As I spent more of my life under the supervision of medical professionals dedicated to enhancing the well-being of others, I observed Bobby cutting nearly half a billion dollars from research into mRNA vaccines.”
She added, “Suddenly, the health care system on which I relied felt strained, shaky” on 22 November . Her critique sets the stage for understanding how these policy actions affected thousands of patients and destabilized the research ecosystem.
A Timeline of Turmoil
Key events outline the unfolding crisis. May 2024: Tatiana diagnosed with AML. January 2025: Caroline Kennedy opposed RFK Jr.’s confirmation. June 2025: 17 ACIP members replaced with vaccine skeptics. August 2025: $500 million mRNA funding terminated.
Historical symmetry underscores the narrative. Tatiana published her essay exactly 62 years after JFK’s assassination. Previous family tragedies amplify the stakes, making the timing of her revelations especially poignant and historically resonant.
Locations Hit Hard
Funding cuts impacted research nationwide. Memorial Sloan Kettering Cancer Center, where Tatiana received treatment, faced uncertain support for breakthrough mRNA cancer vaccines. Emory University and the University of Texas Medical Branch saw major contract cancellations, disrupting ongoing studies.
International researchers were barred from receiving NIH subawards. Dr. Peter Hotez emphasized, “The U.S. remains the largest vaccine market,” warning that global companies could rethink mRNA investments. Could these geographic restrictions redefine U.S. vaccine leadership?
Ideological Clash Exposed
RFK Jr.’s stated rationale: “mRNA vaccines fail to protect effectively against upper respiratory infections like COVID and flu” on 6 August 2025. His longstanding skepticism clashed with decades of public health consensus.
Tatiana highlighted the contradiction: “Cutting nearly half a billion dollars from research into mRNA vaccines—technology potentially beneficial against certain cancers” on 22 November 2025. Her essay questions the balance of ideology versus public health duty.
Political and Fiscal Pressure
The Trump administration emphasized reduced federal spending in January 2025. NIH Director Jay Bhattacharya mandated a review of all research activities, flagging programs not aligned with new priorities as vulnerable to termination.
David Dodd, CEO of GeoVax Labs, noted, “Programs in mid-development stages may be paused or abandoned, clinical trial momentum may be lost, and hiring and investment plans are now being reevaluated” on 17 August 2025. The consequences extend beyond policy into human lives.
Patients at Risk
The 74,311 patients affected faced direct harm. Loss of access to experimental treatments and compromised monitoring created dangerous gaps. Tatiana’s CAR-T therapy trials represented “my only shot at remission” on 22 November 2025.
Harvard’s Dr. Anupam B. Jena warned, “Since grant disruptions and terminations started, questions about the scope of clinical trials affected has been paramount importance” on 16 November 2025. Trust in research continuity is under unprecedented strain.
Pharmaceutical Fallout
Major firms like Moderna lost $1.09 billion in contracts. Pfizer and Sanofi Pre-award solicitations were rejected. Smaller startups faced layoffs, valuation drops, and stalled fundraising, creating cascading instability in biotech and pharmaceutical ecosystems.
A research analyst noted, “Funding cuts slow research and destabilize the entire biotech ecosystem” on 17 August 2025. How companies respond could determine the future of mRNA innovation and cancer therapies in the U.S.
Academic Institutions Disrupted
Emory University lost its mRNA contract entirely. Harvard and other institutions reported attrition and brain drain. Hundreds of NIH staffers signed the “Bethesda Declaration” urging reversal of cuts, signaling a profound crisis in academic research.
The loss of continuity means trials may need to restart from scratch, delaying progress. International collaborations also ended, raising concerns about the long-term global impact of these decisions.
Public Health Consequences
Reduced pandemic preparedness is a pressing concern. Jennifer Nuzzo warned, “When the next pandemic strikes, we will be unprepared” Over 120 mRNA cancer vaccine trials risk collapse, threatening patient outcomes.
Public confidence in mRNA technology erodes. Tatiana observed, “Suddenly, the health care system on which I relied felt strained, shaky” on 22 November 2025. The public health system faces new strains and uncertainty.
Economic and Employment Strain
Job losses are evident. NIH terminations led to agency reductions, clinical trial coordinator positions were eliminated, and major pharmaceutical firms announced hiring freezes. Venture capital retrenched from mRNA platforms, adding financial instability.
Tatiana’s perspective highlights the human cost: “I worried about funding for leukemia and bone marrow research at Memorial Sloan Kettering, as well as the trials that represented my only shot at remission”. The ripple effects of policy decisions are far-reaching.
Tatiana’s Critique Summarized
Tatiana blasts RFK Jr. as “an embarrassment to me and the rest of my immediate family”. Her essay illustrates a deeply personal and historical reckoning with policy choices that imperil public health and research.
Through her terminal illness, she exposes the human and systemic cost of funding terminations. Her voice embodies the clash of family loyalty, public responsibility, and the fragility of life-saving research.